Current view on gut microbiota;Actualité du microbiote intestinal

Annales Pharmaceutiques Francaises

Volumn 72, Issue 1, 2014, Pages 15-21

  Bourlioux, P ^a  

^a NONE   (France)

Author keywords

Composition; Environment; Functions; Gut microbiota; Health; Medicines; Protection; Xenobiotics

Indexed keywords

PESTICIDE; XENOBIOTIC AGENT; POLLUTANT; PROBIOTIC AGENT;

AUTISM; BEHAVIOR DISORDER; CROHN DISEASE; DYSBIOSIS; INTESTINE FLORA; METABOLIC CAPACITY; METABOLIC SYNDROME X; METAGENOMICS; OBESITY; PHYSIOLOGY; POLLUTANT; SHORT SURVEY; SYMBIOSIS; ULCERATIVE COLITIS; ALTERNATIVE MEDICINE; ANIMAL; BACTERIAL TRANSLOCATION; EMBRYOLOGY; FECES; GROWTH, DEVELOPMENT AND AGING; HUMAN; INFLAMMATION; INTESTINE; MAMMAL; MICROBIOLOGY; MICROFLORA; PHARMACOKINETICS;

ANIMALS; BACTERIAL TRANSLOCATION; COMPLEMENTARY THERAPIES; ENVIRONMENTAL POLLUTANTS; FECES; HUMANS; INFLAMMATION; INTESTINES; MAMMALS; MICROBIOTA; PROBIOTICS; SYMBIOSIS; XENOBIOTICS;

EID: 84892509992     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2013.09.001     Document Type: Short Survey

References (63)

1. Corthier G. Bonnes bactéries et bonne santé 2011, Éd.Quae INRA, Versailles.
2. Blaser M., Bork P., Fraser C., Knight R., Wang J. The microbiome explored: recent insights and future challenges. Nature Rev Microbiol 2013, 11:213-217.
3. Holzman D.C. Major host health effects ascribed to gut microbiome. Microbe 2011, 6(6):235.
4. Goto Y., Ivanov I.I. Intestinal epithelial cells as mediators of the commensal-host immune crosstalk. Immunol Cell Biol 2013, 91:204-214.
5. Lathrop S.K., Bloom S.M., Rao S.M., Nutsch K., Lio C.W., Santacruz N., et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 2011, 478:250-254.
6. Maynard C., Elson C.O., Hatton R.D., Weaver C.T. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241.
7. Gallo R.L., Hooper L.V. Epithelial antimicrobial defence of the skin and intestine. Nature Rev Immunol 2012, 12:503-517.
8. Fraher M.H., O'Toole P.W., Quigley E.M.M. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012, 9(6):312-322.
9. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
10. The human microbiome project consortium. Structure, functions and diversity of the healthy human microbiome. Nature 2012;486:207-14.
11. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., et al. Diversity of the human intestinal microflora. Science 2005, 308:1635-1638.
12. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
13. Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230.
14. Rothe M., Blaut M. Evolution of the gut microbiota and the influence of diet. Benef Microbes 2013, 4(1):31-37.
15. Blaser M. Antibiotic overuse: stop the killing of beneficial bacteria. Nature 2011, 476:393-394.
16. Cho I., Yamanishi S., Cox L., Methé B.A., Zavadil J., Li K., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012, 488:621-626.
17. Pérez-Cobas A.L., Gosalbes M.J., Friedrichs A., Knecht H., Artacho A., Eismann K., et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 2012, [Gut.Published on line First 11 december 2012, Epub ahead of print]. 1031136/gutjnl-2012-303184.
18. Yu L.C., Wang J.T., Wei S.C., Ni Y.H. Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. World J Gastrointest Pathophysiol 2012, 3(1):27-43.
19. Cani P.D., Possemiers S., Van de Wiele T., Guiot Y., Everard A., Rottier O., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58(8):1091-1103.
20. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermúdez-Humarán L.G., Gratadoux J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008, 105(43):16731-16736.
21. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., et al. Host-gut microbiota metabolic interactions. Science 2012, 336:1262-1267.
22. Bäckhed F., Hao D., Wang T., Hooper L.V., Koh G.Y., Nagy A., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101(44):15718-15723.
23. DiBaise J.K., Zhang H., Crowell M.D., Krajmalnik-Brown R., Decker G.A., Rittmann B.E. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008, 83(4):460-469.
24. Collins S.M., Surette M., Bercik P. The interplay between the intestinal microbiota and the brain. Nature Rev Microbiol 2012, 10:735-742.
25. Franks I. Microbiota: gut microbes might promote intestinal angiogenesis. Nat Rev Gastroenterol Hepatol. 2013, 10(1):3.
26. Pluznick J.L., Protzko R.J., Gevorgyan H., Peterlin Z., Sipos A., Han J., et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A 2013, 110:4410-4415.
27. Markle J.G.M., Frank D.N., Mortin-Toth S., Robertson C.E., Feazel L.M., Rolle-Kampczyk U., et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 2013, 339:1084-1088.
28. Kamada N., Seo S.U., Grace Y., Chen G.Y., Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nature Rev Immunol 2013, 13:321-336.
29. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328(5975):228-231.
30. Koeth R.A., Wang Z., Levison B.S., Buffa J.A., Org E., Sheehy B.T., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Med 2013, 19(5):576-585.
31. Björkstén B. Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin Immunopathol 2004, 25(3-4):257-270.
32. Finegold S.M. State of the art; microbiology in health and disease. Intestinal bacterial flora in autism. Anaerobe 2011, 17(6):367-368.
33. Benach J.L., Li E., McGovern M.M. A microbial association with autism. MBio 2012, 3(1). [pii: e00019-12].
34. Diaz Heijtz R., Wang S., Anuar F., Qian Y., Björkholm B., Samuelsson A., et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 2011, 108(7):3047-3052.
35. Bailey M.T., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun 2011, 25(3):397-407.
36. Winter S.E., Lopez C.A., Bäumler A.J. The dynamics of gut-associated microbial communities during inflammation. EMBO Rep 2013, 14(4):319-327.
37. Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease: review. Nature Rev Immunol 2009, 9:313-323.
38. Aroniadis O.C., Brandt L.J. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013, 29(1):79-84.
39. Association for Professionals in infection control and epidemiology (APIC) Implementation Guide. Guide to preventing C.difficile infections 2013:81-5, Washington []. http://apic.org/Resource_/EliminationGuideForm/59397fc6-3f90-43d1-9325-e8be75d86888/File/2013CDiffFinal.pdf.
40. Aroniadis O.C., Brandt L.J. Fecal Microbiota Transplantation. Curr Opin Gastroenterol 2013, 29(1):79-84.
41. Brandt L.J., Aroniadis O.C. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013, 78(2):240-249.
42. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. New Engl J Med 2013, 368:407-415.
43. Lenoir-Wijnkoop I., Sanders M.E., Cabana M.D., Caglar E., Corthier G., Rayes N., et al. Probiotic and prebiotic influence beyond the intestinal tract. Nutr Rev 2007, 65(11):469-489.
44. van Baarlen P., Troost F., van der Meer C., Hooiveld G., Boekschoten M., Brummer R.J., et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A 2011, 108(Suppl.1):4562-4569.
45. Hörmannsperger G., Haller D. Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease. Int J Med Microbiol 2010, 300(1):63-73.
46. Sonnenburg J.L., Chen C.T., Gordon J.I. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol 2006, 4(12):e413.
47. Institut Pasteur de Lille. Actes du colloque: Santé-Environnement 18novembre 2010.
48. Breton J., Daniel C., Dewulf J., Pothion S., Froux N., Sauty M., et al. Gut microbiota limits heavy metals burden caused by chronic oral exposure. Toxicol Lett 2013, [pii: S0378-4274(13)01249-56].
49. Zhai Q., Wang G., Zhao J., Liu X., Tian F., Zhang H., et al. Protective effects of Lactobacillus plantarum CCFM8610against acute cadmium toxicity in mice. Appl Environ Microbiol 2013, 79(5):1508-1515.
50. Foligné B. Communication personnelle au cours de l'audition du 24/09/2012.
51. Halttunen T., Salminen S., Tahvonen R. Rapid removal of lead and cadmium from water by specific lactic acid bacteria. Int J Food Microbiol 2007, 114(1):30-35.
52. Bhakta J.N., Ohnishi K., Munekage Y., Iwasaki K., Wei M.Q. Characterization of lactic acid bacteria-based probiotics as potential heavy metal sorbents. J Appl Microbiol 2012, 112(6):1193-1206.
53. Valls M., Atrian S., de Lorenzo V., Fernández L.A. Engineering a mouse metallothionein on the cell surface of Ralstonia eutropha CH34for immobilization of heavy metals in soil. Nat Biotechnol 2000, 18(6):661-665.
54. Sousa T., Paterson R., Moore V., Carlsson A., Abrahamsson B., Basit A.W. The gastrointestinal microbiota as a site for the transformation of drugs. Int J Pharm 2008, 363:1-25.
55. Rowland I.R. Interactions of the gut microflora and the host in toxicology. Toxicol Pathol 1988, 16:147-153.
56. Haiser H.J., Turnbaugh P.J. Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res 2013, 69(1):21-31.
57. Aura A.M., Mattila I., Hyotylainen T., Gopalacharyulu P., Bounsaythip C., Oresic M., et al. Drug metabolome of the Simvastatin formed by human intestinal microbiota in vitro. Mol Biosyst 2011, 7:437-446.
58. Haiser H.J., Gootenberg D.B., Chatman K., Sirasani G., Balskus E.P., Turnbaugh P.J. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 2013, 341:295-298.
59. Aziz R.K., Saad R., Rizkallah M.R. PharmacoMicrobiomics or how bugs modulate drugs: an educational initiative to explore the effects of human microbiome on drugs. BMC Bioinforma 2011, 12:A10.
60. Olle B. Medicines from microbiota. Nature Biotechnol 2013, 31:309-315.
61. Eiseman B., Silen W., Bascom G.S., Kauvar A.J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44:854-859.
62. Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nature Rev Gastroenterol Hepatol 2012, 9:88-96.
63. Blasco-Baque V., Serino M., Burcelin R. La thérapie métabolique à l'interface entre l'homme et le microbiote intestinal. Ann Pharm Fr 2013, 71(1):34-41.